Company news: GlaxoSmithKline

Share this article:
The decision by FDA and its European counterpart to sharply restrict Avandia is a sharp blow to GSK, which will see sales of the onetime blockbuster dwindle to almost nothing, but the company has already largely dismantled its sales force for the diabetes drug. “We have one small selling team focused on Avandia in the US, but as part of some recent sales force restructuring and in light of what's already happened in the marketplace, we had begun shifting resources to other medicines in the portfolio,” a spokesperson told MM&M. Global sales of the drug were down 18% for the first half of 2010, to around $504 million ($257 million in the US). The company anticipates second half sales of between $157 million and $235 million, “and with minimal annual sales thereafter.” GSK halted all consumer advertising for the drug several years back and ended professional-directed advertising in June.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.